• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Kullback William J

    12/5/23 4:36:40 PM ET
    $DNAY
    Medical Specialities
    Health Care
    Get the next $DNAY alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    KULLBACK WILLIAM J

    (Last) (First) (Middle)
    C/O TELESIS BIO INC.
    10431 WATERIDGE CIRCLE, SUITE 150

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    08/28/2023
    3. Issuer Name and Ticker or Trading Symbol
    Telesis Bio Inc. [ TBIO ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ William J. Kullback 12/05/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DNAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNAY

    DatePrice TargetRatingAnalyst
    3/2/2022Outperform
    Cowen
    10/15/2021Outperform
    Cowen
    7/13/2021$23.00Buy
    Jefferies
    7/13/2021Outperform
    Cowen & Co.
    7/13/2021$30.00Overweight
    Keybanc
    More analyst ratings

    $DNAY
    SEC Filings

    See more
    • Codex DNA Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Telesis Bio Inc. (0001850079) (Filer)

      11/30/23 5:00:12 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Codex DNA Inc.

      10-Q - Telesis Bio Inc. (0001850079) (Filer)

      11/13/23 4:32:50 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Codex DNA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Telesis Bio Inc. (0001850079) (Filer)

      11/13/23 4:32:03 PM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results

      -- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer leveraging Telesis Bio's SOLA platform for enzymatic DNA synthesis technology SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today pre-announced certain preliminary, unaudited financial results for the fourth quarter ended December 31, 2022. The results are subject to the completion of the Company's year-end financial reporting processes, reviews, and audit. Telesis Bio also announced that it has a

      1/9/23 9:00:00 AM ET
      $DNAY
      $TBIO
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Inc. Reports Third Quarter 2022 Financial Results

      -- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te

      11/8/22 4:10:00 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8

      SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve

      11/2/22 4:19:04 PM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $DNAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Cowen resumed coverage on Codex DNA

      Cowen resumed coverage of Codex DNA with a rating of Outperform

      3/2/22 8:41:22 AM ET
      $DNAY
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Codex DNA

      Cowen resumed coverage of Codex DNA with a rating of Outperform

      10/15/21 7:20:31 AM ET
      $DNAY
      Medical Specialities
      Health Care
    • Jefferies initiated coverage on Codex DNA with a new price target

      Jefferies initiated coverage of Codex DNA with a rating of Buy and set a new price target of $23.00

      7/13/21 6:31:09 AM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Codex DNA Inc. (Amendment)

      SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

      7/5/23 1:28:27 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Codex DNA Inc. (Amendment)

      SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

      7/5/23 1:24:55 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form SC 13D filed by Codex DNA Inc.

      SC 13D - Telesis Bio Inc. (0001850079) (Subject)

      6/15/23 4:17:49 PM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Kullback William J

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      12/5/23 4:38:19 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Kullback William J

      3 - Telesis Bio Inc. (0001850079) (Issuer)

      12/5/23 4:36:40 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Herrema Gregory J. was granted 153,191 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      10/25/23 2:46:10 PM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    Financials

    Live finance-specific insights

    See more
    • Telesis Bio Inc. Reports Third Quarter 2022 Financial Results

      -- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te

      11/8/22 4:10:00 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8

      SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve

      11/2/22 4:19:04 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Codex DNA Reports Second Quarter 2022 Financial Results

      SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. Recent HighlightsContinued execution across all areas of the growth strategy: Increased total revenue by 98% over prior year periodGrew revenue by 44% on an organic basis year over year, excluding contributions from Eton Bioscience acquisitionDelivered solid growth in BioXp 3250 instrument placementsExperienced record high BioXp kit revenues, driven by growth in gene fragments, cloning, and DNA library kitsLaunched MyBioXperience, a new e-commerce solution, which dramatically sim

      8/9/22 4:10:00 PM ET
      $DNAY
      Medical Specialities
      Health Care